Mazzali · Hypertension (Dallas, Tex. : 1979) 2001 · controlled animal experiment · n=?

Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.

Cited 1304 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal laboratory study.

PubMed 11711505 · doi:10.1161/hy1101.092839 · record verified 2026-08-29

What was done

Mild hyperuricemia was induced in rats using the dietary uricase inhibitor oxonic acid. Blood pressure and kidney histology were assessed alongside interventions including uric acid-lowering agents (allopurinol, benziodarone), oxonic acid withdrawal, and pathway inhibitors (enalapril, L-arginine). Immunohistochemistry evaluated collagen deposition, macrophage infiltration, osteopontin expression, juxtaglomerular renin, and macula densa neuronal nitric oxide synthase (NOS).

What was found

Hyperuricemic rats developed elevated blood pressure after 3 weeks, while controls remained normotensive. Hypertension was prevented or reversed by allopurinol, benziodarone, or oxonic acid withdrawal. Blood pressure correlated directly with serum uric acid (r = 0.75, n = 69), with a 10-mm Hg increase per 0.03-mmol/L (0.5-mg/dL) rise in uric acid. Kidneys showed no urate crystals but demonstrated ischemic injury (collagen deposition, macrophage infiltration, osteopontin expression), increased renin, and decreased neuronal NOS. Renal injury and hypertension were both attenuated by enalapril or L-arginine.

Why it matters

This study provides experimental evidence that elevated uric acid can directly induce hypertension and microvascular renal damage independently of crystal deposition, mediated by renin-angiotensin system activation and nitric oxide reduction.

Limits

Findings are limited to a rodent model using pharmacological uricase inhibition; rats differ substantially from humans who naturally lack uricase. Total sample sizes and group breakdowns are not fully detailed in the abstract.

Cited by